<DOC>
	<DOC>NCT01814189</DOC>
	<brief_summary>The purpose of this study is to show the efficacy of promethazine in management of patients with moderate to severe migraine</brief_summary>
	<brief_title>Efficacy and Safety of Oral Sumatriptan Plus Oral Promethazine in Migraine Treatment</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Migraine without Aura</mesh_term>
	<mesh_term>Migraine with Aura</mesh_term>
	<mesh_term>Sumatriptan</mesh_term>
	<mesh_term>Promethazine</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<criteria>Patients who aged 18 to 65 years with a clinical history of migraine with or without aura (International Headache Society categories 1.1 or 1.2) for at least 1 year Subjects who have mean frequency of 28 migraine attacks per month. Complex form of migraine, medication overuse headache, history of chronic tensiontype headache, ophthalmoplegic, basilar and hemiplegic migraine Uncontrolled hypertension (diastolic blood pressure &gt;95 mm Hg or systolic blood pressure &gt;160 mm Hg) History or clinical evidence of cerebrovascular or cardiovascular disorder Renal impairment or dialysis dependence Serious illness (physical or psychiatric disorders) Drugs and alcohol abuse Pregnancy and breastfeeding Allergy or hypersensitivity to promethazine or triptans Concurrent use of ergotaminecontaining drugs, monoamine oxidize inhibitors, antidepressant, lithium</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>